Kroczek R A, Graf D, Brugnoni D, Giliani S, Korthüer U, Ugazio A, Senger G, Mages H W, Villa A, Notarangelo L D
Molecular Immunology, Robert Koch-Institute, Berlin, Germany.
Immunol Rev. 1994 Apr;138:39-59. doi: 10.1111/j.1600-065x.1994.tb00846.x.
X-linked immunodeficiency with hyper-IgM (HIGM1) is a rare disorder, characterized by recurrent infections associated with very low or absent IgG and IgA, and normal to increased IgM serum levels. The disease has been earlier mapped to the q26-27 region of the X-chromosome. We have identified a novel molecule expressed on the surface of activated T cells, which was designated TRAP (Tumor necrosis factor Related Activation Protein), and could demonstrate that TRAP is a ligand for the CD40 receptor expressed on B cells. Our mapping of the TRAP gene to the Xq26.3-27.1 region suggested a causal relationship to HIGM1. Further work revealed that various mutations of the TRAP/CD40 ligand (CD40L) gene may lead to a defective expression of the TRAP/CD40L molecule on the T-cell surface in HIGM1 patients. A combination of structural and functional analyses finally demonstrated that the failure of TRAP/CD40L on T cells to interact with CD40 on B cells is responsible for the inefficient T-cell help for B cells observed in HIGM1. The observations made in HIGM1 allowed us to conclude that TRAP/CD40L is not required for IgM synthesis. In contrast, functional expression of TRAP is a prerequisite for effective immunoglobulin isotype switching and subsequent production of IgG, IgA and IgE by B cells in vivo. The interaction of TRAP/CD40L with CD40 thus provides a very critical link between the cellular and the humoral part of the immune system. The knowledge of TRAP/CD40L cDNA sequence, the availability of various reagents for the testing of expression and function of TRAP/CD40L, and our recent elucidation of the exon-intron structure of the TRAP/CD40L gene now provide all necessary tools for early diagnosis of affected patients and the detection of female carriers of HIGM1. The available information will also provide a basis for future attempts at gene therapy in this disease.
X连锁高IgM免疫缺陷症(HIGM1)是一种罕见疾病,其特征为反复感染,伴有极低水平或缺乏IgG和IgA,而血清IgM水平正常或升高。该疾病先前已被定位到X染色体的q26 - 27区域。我们鉴定出一种在活化T细胞表面表达的新分子,命名为TRAP(肿瘤坏死因子相关激活蛋白),并证实TRAP是B细胞上表达的CD40受体的配体。我们将TRAP基因定位到Xq26.3 - 27.1区域,提示其与HIGM1存在因果关系。进一步研究发现,TRAP/CD40配体(CD40L)基因的各种突变可能导致HIGM1患者T细胞表面TRAP/CD40L分子表达缺陷。结构和功能分析相结合最终表明,T细胞上的TRAP/CD40L无法与B细胞上的CD40相互作用,是HIGM1中观察到的T细胞对B细胞辅助功能低下的原因。在HIGM1中的观察结果使我们得出结论,IgM合成不需要TRAP/CD40L。相反,TRAP的功能性表达是B细胞在体内有效进行免疫球蛋白同种型转换并随后产生IgG、IgA和IgE的前提条件。因此,TRAP/CD40L与CD40的相互作用在免疫系统的细胞和体液部分之间提供了一个非常关键的联系。TRAP/CD40L cDNA序列的知识、用于检测TRAP/CD40L表达和功能的各种试剂的可用性,以及我们最近对TRAP/CD40L基因外显子 - 内含子结构的阐明,现在为受影响患者的早期诊断和HIGM1女性携带者的检测提供了所有必要工具。现有信息也将为该疾病未来的基因治疗尝试提供基础。